To Assess the Patients’ Ability to Self-Administer Fasinumab

Overview

The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical performance of the device. The secondary objectives of the study are: – To evaluate the successful injection of fasinumab by patients or their caregivers using the AI in an unsupervised setting – To evaluate patient/caregiver satisfaction with the AI for fasinumab injection in an unsupervised setting – To evaluate exposure in serum for fasinumab administered by patients or their caregivers using an AI in an unsupervised setting, or fasinumab administered by study staff using a PFS that has been used in the phase 3 program – To characterize the safety, tolerability, and immunogenicity of fasinumab administered by patients or their caregivers using an AI in an unsupervised setting, or fasinumab administered by study staff using a PFS that has been used in the phase 3 program

Full Title of Study: “A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients’ Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 15, 2020

Interventions

  • Drug: Fasinumab AI
    • Self-administered with auto injector
  • Drug: Fasinumab PFS
    • Prefilled syringe administered by study staff

Arms, Groups and Cohorts

  • Experimental: Auto-injector (AI)
  • Experimental: Prefilled syringe (PFS)

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of device-associated product technical failure (PTF) for the AI based on the total number of fasinumab injections administered by patients/caregivers in an unsupervised setting
    • Time Frame: Baseline to Week 16

Secondary Measures

  • Proportion of successful fasinumab injections administered by patients or their caregivers using an AI in an unsupervised setting (per patient report)
    • Time Frame: Baseline to Week 16
  • Number of AI associated product technical complaint (PTCs)
    • Time Frame: Baseline to Week 16
  • Number of validated AI associated PTFs
    • Time Frame: Baseline to Week 16
  • Number of patients with an AI associated PTC
    • Time Frame: Baseline to Week 16
  • Number of AI use-related errors
    • Time Frame: Baseline to Week 16
    • Including but not limited to improper storage, inappropriate use of the device, dosing schedule mistakes, and user handling mistakes
  • Patient satisfaction with the AI as assessed using the Self-Injection Assessment Questionnaire (SIAQ)
    • Time Frame: Baseline to Week 16
  • Number of participants who experience Adjudicated arthropathy (AA)
    • Time Frame: Through week 36
    • As confirmed by independent adjudication
  • Number of participants who experience Destructive arthropathy (DA)
    • Time Frame: Through week 36
    • As confirmed by independent adjudication
  • Number of participants who experience treatment-emergent adverse events (TEAEs)
    • Time Frame: Through week 16
  • Number of participants who experience sympathetic nervous system dysfunction
    • Time Frame: Through week 36
  • Number of participants who experience peripheral sensory adverse events (AEs) that require a neurology or other specialty consultation
    • Time Frame: Through week 36
  • Number of participants who experience all-cause Joint replacement (JR)s
    • Time Frame: Through week 36
  • Number of participants who experienced JR at the telephone survey
    • Time Frame: 52 weeks after last dose of study drug
  • Maximum observed drug concentration (Cmax)
    • Time Frame: Up to 36 weeks
  • Area under the curve from the time of dosing to the end of dosing interval (AUC)
    • Time Frame: Up to 36 weeks
  • Geometric mean ratio of Cmax and AUC for the AI device (CI) of the geometric mean ratio
    • Time Frame: Up to 36 weeks
  • Geometric mean ratio of Cmax and AUC for the PFS device (CI) of the geometric mean ratio
    • Time Frame: Up to 36 weeks
  • Incidence of anti-drug antibody (ADA)
    • Time Frame: Up to 36 weeks

Participating in This Clinical Trial

Key Inclusion Criteria:

1. A clinical diagnosis of Osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index joint) at the screening visit 2. Moderate-to-severe pain in the index joint defined as a WOMAC average pain subscale score of ≥4 at both the screening and randomization visits 3. Willing to discontinue current pain medications and to adhere to study requirements for rescue treatments 4. A history of at least 12 weeks of analgesic use for pain due to OA of the knee or hip 5. History of regular use of analgesic medications for OA pain (defined as an average of 4 days per week over the 4 weeks prior to the screening visit), including NSAIDs, selective cyclooxygenase 2 inhibitors, opioids, paracetamol/acetaminophen, or combinations thereof Key Exclusion Criteria:

1. History or presence at the screening visit of non-OA inflammatory joint disease (eg,rheumatoid arthritis, lupus erythematosus, psoriatic arthritis, pseudo-gout, gout, spondyloarthropathy, polymyalgia rheumatica, joint infections within the past 5 years), Paget's disease of the spine, pelvis or femur, neuropathic disorders, multiple sclerosis, fibromyalgia, tumors or infections of the spinal cord, or renal osteodystrophy 2. History or presence on imaging of arthropathy (osteonecrosis, subchondral insufficiency fracture, rapidly progressive OA type 1 or type 2), stress fracture, recent stress fracture, neuropathic joint arthropathy, hip dislocation (prosthetic hip dislocation is eligible), knee dislocation (patella dislocation is eligible), congenital hip dysplasia with degenerative joint disease, extensive subchondral cysts, evidence of bone fragmentation of collapse, or primary metastatic tumor with the exception of chondromas or pathologic fractures during the screening period 3. Trauma to the index joint within 3 months prior to the screening visit 4. Signs or symptoms of carpal tunnel syndrome within 6 months of screening 5. Patient is not a candidate for MRI Note: Other protocol defined Inclusion/Exclusion criteria apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Regeneron Pharmaceuticals
  • Collaborator
    • Teva Pharmaceutical Industries, Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Clinical Trial Management, Study Director, Regeneron Pharmaceuticals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.